CFMG & Wellpath in California — a documentary investigation · Article 024 of 100 · Series 3 — Physician executives, ownership and succession

Richard Medrano: One Physician, Two Institutional Roles

Published

20 September 2026, 6:00 PM PT

Content last changed

20 September 2026, 6:00 PM PT

Public-evidence cutoff

20 September 2026, 6:00 PM PT

Sources checked

20 September 2026, 6:00 PM PT

Record through

20 September 2026, 6:00 PM PT

Editorial status

Public-source editorial review complete

Evidence note. This article relies on public records and distinguishes established fact, party position, allegation, judicial finding, inference and unresolved question. Nothing here is a finding that any identified corporation or individual violated California law unless a cited adjudicative source expressly says so.

Opening frame#

Richard Medrano: One Physician, Two Institutional Roles is a governance inquiry, not a title-matching exercise. Corporate office, medical leadership, stock ownership, enterprise employment, and practical decision authority are treated as distinct evidentiary categories. The record is strongest where those categories converge in executed documents and weakest where succession or ownership instruments remain unavailable.

The governing question is narrow: How should a Regional Medical Director and CFMG corporate officer be analyzed when the same person acts in both systems? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material.

I. The Question and the Public Record#

The relevant public record is best read cumulatively. No single branding statement, county agenda item, corporate filing, bankruptcy disclosure, or management agreement resolves the entire relationship. The evidentiary value comes from comparing documents created for different purposes and asking whether they converge on the same allocation of identity, authority, economics, and professional responsibility.

Why this is analytically important#

If the underlying filings truly say what the docket text says, the record raises an obvious question:

How could a California physician-owned professional corporation be identified in federal corporate-disclosure filings as the “corporate parent” of Wellpath LLC, a national management entity, while public corporate materials describe CFMG as a Wellpath affiliate?

There may be an innocent explanation: ECF relationship categories may have been selected imperfectly, the disclosure might have been drafted for conflicts purposes rather than corporate genealogy, or docket metadata may compress a more nuanced statement.

the record must not turn this into an accusation before reviewing the filings themselves.

But the repetition across more than one case means the issue is sufficiently concrete to justify a dedicated source-retrieval project.

open question: Very High.

Requested source set:

• exact PDF of interested-entity/corporate-disclosure filings in Beckner ;

• exact filings in Sand ;

• exact filings in Strieter ;

• exact filings in Avila ;

• equivalent filings in Venegas , Kukar-Tekano , Ayala , Pugh , and current CFMG cases.

The output should be a year-by-year table showing the relationship box or terminology actually used.

A SECOND TITLE ANOMALY: HERR AS "SENIOR REGIONAL MEDICAL DIRECTOR" IN 2021#

An Alameda County amendment dated October 14, 2021 was signed on behalf of CFMG by:

Raymond Herr, M.D. — Senior Regional Medical Director

Yet a Monterey amendment signed only weeks earlier, September 8, 2021, identified him as:

Raymond Herr, M.D. — President

This is an important example of why title data must be source-specific.

It could mean:

• Herr simultaneously held both roles;

• the Alameda signature used an operational title rather than corporate office;

• corporate succession occurred during that short period;

• an old template or authorization was used.

The record does not yet permit a confident conclusion.

The correct status is:

Unresolved title transition — late 2021.

Richard medrano is a particularly important cross-role figure#

Richard Medrano, M.D., emerges as a CFMG corporate officer while simultaneously holding an operational role inside Wellpath.

Public Wellpath proposal materials identify Medrano as a Regional Medical Director and state that he joined Wellpath in 2017.

A 2024 county proposal says he oversees medical services in the West and Southwest region.

CFMG county contracts, meanwhile, identify him as:

• Vice President;

• Vice President & Secretary;

• Corporate Secretary;

• later Secretary.

Thus Medrano occupies both:

• a CFMG corporate-governance role;

• and a Wellpath regional clinical-management role.

This does not automatically undermine CFMG independence.

A physician can serve two affiliated entities.

But dual roles matter because the same physician may be expected to:

• act as a fiduciary/officer of CFMG;

• implement Wellpath regional clinical strategy;

• participate in decisions where the PC and MSO interests differ.

The high-value evidence is therefore conflict handling and actual decision records, not the mere fact of dual titles.

The december 2018 county record is one of the earliest public examples of CFMG/Wellpath identity blending#

Only months after CFMG began operating the Fresno contract, a Fresno County behavioral-health advisory record stated that a name change had recently occurred from CFMG to Wellpath, while also stating that the organization would continue to operate under CFMG and the Fresno contract would remain with CFMG .

The same County record referred to the Fresno agreement as the largest Wellpath contract and described Wellpath operational personnel, including a regional operations director.

Primary County minutes:

https://www.fresnocountyca.gov/files/sharedassets/county/v/1/vision-files/files/35776-dec-2018-minutes.pdf

This is exceptionally useful because it documents the identity ambiguity essentially at the moment it arose.

The County’s language can be summarized:

Public operating name changed to Wellpath; legal contract remained CFMG.

The “name change” wording should not be interpreted as an actual corporate conversion.

Later federal cases and bankruptcy records establish that CFMG did not simply change its legal name to Wellpath.

But the County record explains why employees, patients, counsel, and courts later used the names interchangeably.

Corporate disclosures — affiliate/parent labels as source-tracing material#

Several federal cases include corporate-disclosure entries describing CFMG and Wellpath through “affiliate,” “other affiliate,” or more expansive relationship labels.

These are useful for establishing that a disclosed corporate relationship existed or was represented.

They are poor substitutes for:

• stock ledgers;

• shareholder agreements;

• capitalization tables;

• governance instruments;

• or the MSA.

A Rule 7.1 label should therefore be coded:

relationship representation — authenticate underlying corporate basis.

Exact disclosure language is reproduced here only with:

• case;

• ECF number;

• filing date;

• filing party;

• signatory;

• and surrounding form context.

II. Structural and Historical Context#

III. The Control and Governance Analysis#

Why these documents matter now#

California Attorney General enforcement in 2026 has focused directly on structures in which an MSO or private-equity-backed enterprise can:

• replace a physician shareholder;

• control who succeeds the shareholder;

• make physician ownership dependent on continued use of the MSO;

• prevent the physician practice from replacing the MSO without risking ownership.

That is precisely why the CFMG stock-transfer documents can no longer be treated as incidental corporate paperwork.

The decisive questions are:

• Who could become a CFMG shareholder?

• Who nominated or approved successors?

• Could Wellpath veto a proposed physician shareholder?

• Could Wellpath require replacement of a physician shareholder?

• What happened upon death, disability, loss of licensure, resignation, retirement, termination, or bankruptcy?

• Was any stock held in escrow?

• Did any proxy, option, nominee arrangement, succession list, or power of attorney exist?

• Who fixed the share-purchase price?

• Who funded the purchase?

• Did Wellpath or an affiliate possess a security interest tied to the shares?

• Could a physician owner remain owner after terminating the MSA?

• Could the physician owner sell to another qualified physician without Wellpath approval?

Until these instruments are obtained, no confident conclusion should be made about ultimate ownership succession.

The company-designee mechanism can concentrate CFMG corporate authority#

Section 1.4 of the MSA provides that when CFMG approval, consent, direction, or action is required, the action of the person designated as CFMG's Chief Executive Officer under its bylaws—the Company Designee —constitutes action of CFMG unless otherwise specified.

The management company may assume that required internal CFMG consents and approvals have been obtained.

This can be a commercially efficient agency mechanism.

But it can also become an evidentiary bottleneck.

If extensive CFMG corporate authority passed through one physician officer, the critical questions become:

• who held the Company Designee role each year;

• whether that person was a shareholder;

• whether that person held roles on the Wellpath/MSO side;

• what independent information the designee reviewed;

• whether board/shareholder deliberation occurred;

• whether the designee ever rejected management recommendations.

A structure can be formally physician-controlled while still concentrating all practical PC approval in one physician officer.

That is not automatically unlawful.

It does mean the independence of that office is central.

Reconstructing shareholder identity YEAR BY YEAR#

County contracts provide some direct corporate-signature evidence.

For example, a 2023 Placer County contract was executed for CFMG by:

• J. Bazzel as President;

• R. Medrano, M.D. as Secretary.

The document expressly invokes California Corporations Code section 313 execution formalities.

This supports the existence of functioning CFMG corporate officers.

The complete governance reconstruction should identify by year:

• shareholders;

• directors;

• president/CEO;

• secretary;

• CFO/treasurer;

• Company Designee;

• medical directors;

• any overlapping Wellpath positions.

The goal is not to imply wrongdoing from overlapping roles.

It is to identify which people actually carried the physician-corporation's legal authority.

The same governance record also justifies deeper control review#

Other facts justify investigation rather than a presumption of independence:

• The original MSA was signed by the same CEO on both sides.

• H.I.G. was included in the MSA notice architecture from inception.

• The manager may attend and participate in CFMG governance meetings.

• Company action can be concentrated through a single Company Designee.

• The 2019 assignment transferred stock-transfer restriction agreements into the Wellpath management structure.

• Bazzel came from the pre-merger CCS executive structure.

• Medrano simultaneously holds Wellpath regional medical and CFMG corporate roles.

• CFMG's principal office migrated from California to Wellpath's Tennessee corporate infrastructure.

• Current officers/directors use the same Tennessee administrative locus.

• Current shareholders remain undisclosed in the public evidence.

• The actual stock-succession rules remain missing.

Again, those facts do not establish illegality.

They identify the precise governance records needed to answer the question.

Cross-roles make capacity important#

At least some CFMG directors/officers also have documented roles within the Wellpath/Correct Care enterprise.

That is not unlawful by itself.

A physician may simultaneously:

• serve as a PC director;

• perform clinical leadership for an MSO;

• hold administrative responsibilities.

But the person must be analyzed by capacity .

When a physician signs or votes:

• Was the physician acting for CFMG?

• for Wellpath?

• under a CFMG delegation?

• under a Wellpath job responsibility?

• in both capacities?

If CFMG and Wellpath disagree, a dual-role physician can face a governance conflict even though both positions are medically licensed.

The final record should therefore tag every key actor by:

• employer;

• corporate office;

• board seat;

• shareholder status;

• clinical appointment;

• decision capacity.

Witness map — ask for person, entity, authority, document, and timing#

Future testimony should not begin with “Who controlled CFMG?” That invites conclusory disagreement.

For each event, the witness should be asked to identify:

• person — who acted;

• entity — who employed that person;

• authority — what instrument authorized the act;

• document — what contemporaneous record exists;

• timing — before or after implementation;

• veto — who could stop the action;

• override example — when that veto was actually used.

High-value witness categories:

• CFMG directors/officers;

• Physician Board members;

• Medical Director(s);

• Wellpath HR leadership;

• site HSA;

• Regional/Division operations leadership;

• credentialing leadership;

• IT/HRIS administrator;

• policy owner;

• utilization-review physician;

• corporate secretary/governance custodian;

• County contract administrator where County authority is implicated.

A witness who says “CFMG had final authority” should be asked to identify the specific record showing a CFMG decision in the disputed event. A witness who says “Wellpath terminated the physician” should likewise be asked whether management was recommending, approving, communicating, or implementing.

IV. Contrary Evidence, Limits, and Competing Explanations#

A disciplined analysis must begin its limiting case with the strongest contrary evidence: The central limitation is the missing shareholder/stock-transfer record. Physician corporate titles are genuine governance evidence but are not proof of ownership or independence under disagreement.

Current evidence favoring structural independence#

The strongest evidence favoring genuine structural independence includes:

• CFMG remained a separate nondebtor professional corporation during Wellpath bankruptcy.

• Wellpath's own board co-chair publicly stated there was no ownership overlap.

• County materials describe CFMG as a separate physician-owned entity.

• CFMG signs county contracts through physician corporate officers.

• The MSA expressly preserves professional judgment.

• CFMG possesses contractual rights to terminate for material manager breach.

• Management's governance representative is expressly nonvoting.

• CFMG is the covered entity under HIPAA while management is the business associate.

• CFMG appears to own/hold the professional contracts with California counties.

• The MSA contemplates CFMG board evaluation of management performance and bonus determinations.

These facts are meaningful and must remain in the final analysis.

DHEERAJ TARANATH is distinct from THE VERIFIED CFMG BOARD#

Dr. Dheeraj Taranath is highly relevant to CFMG operations, but the current evidence does not establish him as a CFMG shareholder, director, or officer.

Wellpath's current leadership page identifies him as:

Chief Clinical Officer, Wellpath

The Wellpath bankruptcy plan likewise listed him among the officers of reorganized Wellpath as Chief Clinical Officer.

County materials in 2026 identify him as a Wellpath chief medical/clinical executive.

He has also communicated on CFMG-related matters.

But those facts do not put him on CFMG's board.

This distinction is important because loose shorthand of the form "physician shareholders and leadership" is easy to apply to any senior clinician associated with the enterprise, including Taranath.

For public publication, that shorthand must not become a factual assertion of share ownership.

The correct description is:

Wellpath Chief Clinical Officer who has participated in CFMG-related clinical/organizational matters; no current public proof of CFMG share ownership or board office identified.

Cfmg’s 2025 physician board is strong contrary evidence to a pure shell theory#

California Secretary of State filings from 2025 identify a physician board consisting of:

• Grady Judson Bazzel, M.D.;

• Richard J. Medrano, M.D.;

• Scott Kennedy, M.D.

This is meaningful.

It demonstrates that CFMG has formal physician directors rather than an openly lay board.

It also distinguishes CFMG from structures in which the MSO itself directly holds board seats in the professional corporation.

The unresolved issue is not whether physicians appear in governance.

It is whether those physician directors were free to act independently where their judgment diverged from Wellpath.

That is why real board minutes, rejected recommendations, stock rights, and conflict procedures matter.

V. Missing Documents and Falsification Tests#

The record remains incomplete in material respects. Key unresolved points include the actual shareholder ledger, stock-transfer agreement, succession minutes, and the explanation for contradictory parent/subsidiary/affiliate filings.

The documents that now matter most#

Tier One:

• Every stock-transfer restriction agreement referenced in the 2019 assignment.

• Current CFMG stock ledger.

• Current shareholder agreement.

• Shareholder succession agreements.

• Options, proxies, nominee agreements, powers of attorney.

• CFMG bylaws.

• Company Designee appointments.

• Full Deficit Funding Loan Agreement and amendments.

• UCC-1 financing statements and continuations/terminations.

• Current security agreements.

• Bank signature cards.

• ACH and treasury authorities.

• Deposit-account control agreements.

• 2012 Credit Agreement and successor/refinancing agreements.

• Every MSA amendment since 2012.

• Post-bankruptcy ratification/assumption documents.

• 2025–2026 CFMG board/shareholder minutes.

• Monthly management-company bonus resolutions.

• Management-fee/FMV analyses.

• Current New WPCC Parent capitalization and governance agreements.

Tier Two:

• Intercompany ledgers.

• CFMG general ledger.

• Wellpath management-fee invoices.

• Deficit-funding advance history.

• Insurance/claims agreements.

• IT/data exit provisions.

• county change-of-MSO approval provisions.

• employment/personnel transition restrictions.

• Local Government–California delegation matrix.

• documents showing whether CFMG considered alternative managers during bankruptcy.

CFMG Shareholders, Directors, Officers, Company Designees, Stock Succession, Cross-Roles, and the Search for the Missing Stock-Transfer Agreements#

the prior analysis establishes why ownership succession is the top unresolved structural issue.

the prior analysis should reconstruct:

• every identifiable CFMG shareholder;

• every president/CEO/secretary/CFO;

• every Company Designee;

• overlap with CMGC/Wellpath roles;

• corporate signature history;

• death/resignation/retirement succession events;

• public filings and county contracts;

• historical H.I.G./CMGC transaction representations;

• the most likely repositories for the missing stock agreements.

Only after that chain is reconstructed should the investigation draw any conclusion about who ultimately controlled CFMG ownership.

After six volumes, the most important remaining structural question is ownership.

This article produces a significant clarification:

The public record now permits a reasonably strong reconstruction of CFMG's corporate officers and directors over time, but it still does not identify the current CFMG shareholders or their percentages with sufficient reliability.

That distinction is critical.

A person can be:

• a physician;

• an officer;

• a director;

• a president;

• a chief executive officer;

• a Company Designee under the MSA;

• a medical director;

• a Wellpath executive;

• and even the person signing CFMG contracts

without necessarily being a shareholder.

Conversely, a shareholder may hold no public operating title.

Accordingly, officer succession cannot be treated as proof of stock succession .

The strongest current governance evidence is:

• the 2012 MSA;

• county contracts signed under California corporate formalities;

• California Secretary of State Statements of Information;

• federal litigation;

• labor agreements;

• the Wellpath bankruptcy;

• Wellpath public corporate materials.

Those records establish who held many formal offices.

They do not disclose the stock ledger.

The stock-transfer restriction agreements expressly referenced in the 2019 assignment therefore remain the single most important missing ownership source.

November 21, 2025 — the officer/director roster remains the same, but the principal office moves#

A second California Secretary of State Statement of Information filed November 21, 2025 , File No. BA20252267299 , identifies the same officers:

• Grady Judson Bazzel — CEO

• Richard J. Medrano — Secretary

• Scott Kennedy — CFO

and the same three directors:

• Bazzel;

• Medrano;

• Kennedy.

But the corporate-address picture changes.

The principal office becomes:

6550 Carothers Parkway, Suite 500, Franklin, Tennessee 37067

while the mailing address and officer/director addresses remain:

3340 Perimeter Hill Drive, Nashville, Tennessee 37211

The filing lists no California office .

This is a meaningful administrative fact.

The Franklin address is publicly identified as Wellpath's current headquarters.

Thus by late 2025 CFMG's principal-office filing had moved from the prior Nashville Wellpath location to the reorganized Wellpath headquarters in Franklin.

That is strong evidence of corporate-administrative integration.

It is not evidence of stock ownership.

The current shareholder question remains unanswered#

This is perhaps the most important conclusion of the prior analysis.

The January and November 2025 California Statements of Information tell us:

• officers;

• directors;

• addresses.

They do not tell us:

• shareholders;

• share percentages;

• stock certificates;

• beneficial ownership;

• succession rights.

Wellpath has publicly described CFMG as physician-owned.

Kip Hallman publicly described it as owned primarily by a group of physicians and said there was no ownership overlap with Wellpath.

Those are meaningful corporate statements.

But the actual ownership schedule has not yet been obtained.

Accordingly, the record should not publish:

• "Bazzel owns CFMG";

• "Bazzel, Medrano and Kennedy are the shareholders";

• "Taranath is a CFMG shareholder";

• "Wellpath owns CFMG";

• "H.I.G. owns CFMG stock."

None of those propositions is currently established by sufficiently reliable primary evidence.

The stock-transfer restrictions could explain the succession pattern — but the documents are missing#

The 2019 assignment's express reference to "relevant stock transfer restriction agreements" becomes more important when placed beside the officer succession.

At least three major physician-leadership transitions occurred:

• Fithian era → Herr era;

• Herr era → transitional O'Bryan/Bazzel period;

• Bazzel era → current three-director board.

The unresolved question is whether any of these officer transitions coincided with stock succession.

Questions:

• Did Fithian sell or transfer shares?

• Did Herr acquire shares?

• Did Bazzel acquire shares?

• Were Medrano or Kennedy issued shares?

• Was a single physician shareholder replaced while board offices changed around that person?

• Did Wellpath or its predecessor have contractual approval over the transferee?

• Was stock held subject to a transfer restriction favoring the MSO?

• Did a physician's employment status affect ownership?

Those questions cannot be answered from public officer titles.

The stock documents are necessary.

THE WELLPath CFMG / CFMG HOLDINGS ENTITY MAY HELP EXPLAIN HISTORICAL CONFUSION ABOUT "PARENT" STATUS#

The discovery that Wellpath CFMG, Inc. was formerly CFMG Holdings Corp. provides a new interpretive clue.

Federal and other records have at times used descriptions such as:

• CFMG parent;

• CFMG subsidiary;

• CFMG affiliate;

• CMGC parent.

Some of those descriptions may reflect genuine relationships.

Some may reflect shorthand.

And some may be complicated by the coexistence of:

• the professional corporation;

• CFMG Holdings Corp.;

• Correctional Medical Group Companies;

• Wellpath CFMG, Inc.;

• Wellpath Management.

This is especially important for the unresolved Rule 7.1 corporate-disclosure anomaly identified in the prior analysis.

The correct next step is not to infer that the disclosures are wrong.

It is to retrieve the exact filed forms and identify which legal CFMG entity the disclosure actually names .

The naming collision is a plausible source of confusion, but that remains an inference until the filings are reviewed.

Primary documents now required to complete the ownership chain#

The next document-production/retrieval priority is:

• CFMG stock ledger from 2012 to present.

• Every issued/cancelled stock certificate.

• Shareholder roster by year.

• Share percentages.

• CFMG shareholder agreements.

• Stock-transfer restriction agreements referenced in 2019 assignment.

• Buy-sell agreements.

• succession agreements.

• options.

• proxies.

• nominee/custodial agreements.

• death/disability succession provisions.

• license-loss succession provisions.

• employment-linked stock provisions.

• retirement/resignation transfers.

• board approvals of every stock transfer.

• shareholder approvals.

• valuations/purchase-price records.

• source of funds for each transfer.

• any MSO consent/veto rights.

• any security interest involving shares.

• all Company Designee appointments.

• bylaws from 2012 to present.

• articles/amendments.

• Statements of Information for every year available.

• board/director minutes.

• shareholder meeting minutes.

• written consents.

• conflict-of-interest policies.

• 2012 MSA approval resolutions.

• 2019 assignment approval resolutions.

• post-bankruptcy MSA ratification/continuation resolutions.

• 2026 Local Government–California authorization records.

Why bankruptcy is a true governance stress test#

The ordinary PC–MSO relationship asks whether a physician-owned professional corporation is genuinely independent while buying administrative support from a management company.

Chapter 11 adds a much harder question:

What does the physician corporation do when its exclusive manager becomes insolvent, enters Chapter 11, changes owners, and reorganizes the operating structure?

For an independent principal, that event should at least create the possibility of:

• evaluating the manager’s solvency;

• assessing contract breach/default rights;

• evaluating alternative managers;

• deciding whether to continue the MSA;

• reassessing management fees;

• obtaining independent legal advice;

• examining data/records continuity;

• considering malpractice and insurance continuity;

• evaluating effects on physician employment;

• approving any required assignment or post-emergence transition;

• and documenting the physician board’s judgment.

A decision to remain with Wellpath could be entirely rational.

The test is not whether CFMG changed managers.

The test is whether CFMG exercised an identifiable independent corporate choice .

To date, this investigation has not identified publicly filed CFMG board minutes, shareholder resolutions, independent-counsel memoranda, or other CFMG-specific governance records documenting such a decision.

That absence must be interpreted cautiously.

CFMG was a nondebtor professional corporation. Its internal board materials were not necessarily required to be filed in the Wellpath bankruptcy.

Thus the correct conclusion is not:

“CFMG’s board did nothing.”

The correct conclusion is:

The public bankruptcy record reviewed to date contains extensive evidence of what Wellpath’s Debtors sought to preserve in the PC relationships, but comparatively little public evidence of what CFMG’s physician board independently decided about continuing that relationship.

That asymmetry itself defines the next documentary inquiry.

The bankruptcy motion directly confirms stock-transfer agreements#

Before the bankruptcy review, the strongest evidence of CFMG stock-transfer restrictions came from the January 2019 assignment, which expressly transferred related instruments including “relevant stock transfer restriction agreements.”

Docket No. 15 materially strengthens that evidence at the enterprise level.

The Debtors disclosed that, in addition to PC Management Services Agreements, they and certain physician owners were parties to:

Stock Transfer Agreements

that:

• restrict transfer of a physician owner’s stock;

• facilitate a streamlined transition of ownership;

• promote compliance with state professional-entity requirements;

• address transfer events such as death and disability;

• promote continuity of care;

• and promote the continuation of administrative services by the Debtors .

The Debtors further stated:

Under the Stock Transfer Agreements, the Debtors have authority to ensure that the Professional Corporation is duly licensed and qualified.

This is one of the most important new findings in the entire record.

It establishes that stock-transfer arrangements were not merely passive restrictions designed to prevent transfer to an unlicensed person.

At least at the enterprise level, the Debtors themselves described the agreements as tools tied to:

• ownership transition;

• licensing continuity;

• and continuation of the Debtors’ management relationship.

That is precisely the type of contractual architecture California’s 2026 Art Center and Carbon Health enforcement developments make significant.

But a crucial limitation remains.

Docket No. 15 speaks generically about “certain PC Physicians.”

It does not publish the CFMG-specific Stock Transfer Agreement or state that every provision described applies identically to CFMG.

The CFMG connection is nevertheless stronger than a generic inference because the 2019 CFMG assignment independently confirms that relevant stock-transfer restriction agreements existed in the CFMG relationship .

The two sources therefore fit together:

2019 CFMG Assignment: CFMG-related stock-transfer restrictions existed and were assigned into the Wellpath structure.

2024 PC Motion: Wellpath explains the purposes and functions of Stock Transfer Agreements in its friendly-PC model generally.

The remaining question is the exact CFMG text.

The missing CFMG board record should not be treated as evidence of absence#

Because CFMG was a nondebtor, its ordinary board minutes would normally remain private corporate records.

A bankruptcy court generally does not require every nondebtor counterparty to publish internal deliberations merely because its contract partner files Chapter 11.

Therefore:

No public CFMG board minutes found ≠ no CFMG board deliberation occurred.

But where the substantive question is physician independence, those records become the best direct evidence.

The public record should therefore say:

No publicly filed CFMG board record has yet been identified showing how its physicians evaluated the manager’s bankruptcy and ownership transition.

That is accurate and neutral.

2025 SECRETARY OF STATE FILINGS SHOW A PHYSICIAN BOARD DURING THE BANKRUPTCY ERA#

Project records from the California Secretary of State identify, in January 2025:

• Grady Judson Bazzel — Chief Executive Officer / Director;

• Richard J. Medrano — Secretary / Director;

• Scott Kennedy — Chief Financial Officer / Director.

That means the formal CFMG board during the bankruptcy period was physician-composed.

This is meaningful evidence favoring the formal professional-corporation structure.

It also allows the governance question to be framed concretely:

What did Bazzel, Medrano, and Kennedy decide, in their CFMG capacities, about the Chapter 11 and continuation of the Wellpath MSA?

That is much more useful than asking abstractly whether “CFMG” approved the reorganization.

OVERFIELD — FORMAL SEPARATENESS, SHARED INSTITUTIONAL KNOWLEDGE#

Case: Overfield et al. v. Wellpath Community Care, LLC et al. , E.D. Cal. No. 2:24-cv-00199-TLN-AC.

Overfield presents the opposite analytical problem from Smith .

The entities remain separately captioned.

Yet the corporate-witness record shows deep operational integration.

On May 26, 2026, CFMG produced Heather Hole as its Rule 30(b)(6) person most knowledgeable regarding the termination of former physician Ross Chapman.

Hole testified:

“I actually work for Wellpath, not for California Forensic Medical Group.”

She identified herself as Wellpath’s Senior Vice President of Human Resources.

She also testified that CFMG employees are paid by CFMG and that she would not consider them Wellpath employees.

Those two statements are not inconsistent.

They precisely express the PC–MSO employment architecture:

• CFMG formal employer;

• Wellpath HR administrator.

But the termination testimony goes further.

Asked whether Wellpath terminated Chapman, Hole testified:

“He was terminated by management, which worked for Wellpath.”

The transcript further shows that Hole reviewed Chapman’s termination file to prepare for CFMG’s Rule 30(b)(6) deposition.

This is some of the strongest evidence in the record because it comes from:

• CFMG’s designated corporate witness;

• sworn testimony;

• concerning a physician employment event;

• based on the termination file.

The unresolved question is final authority.

The testimony proves Wellpath-management participation.

It does not yet establish:

• the identity of the final decision-maker;

• whether a CFMG physician independently approved termination;

• whether the reason implicated clinical competency.

The physician-governance body remains undocumented#

Public corporate records identify CFMG physician directors and officers. Whether the same individuals participated in particular personnel decisions is not established by any public record reviewed here. This analysis therefore does not publish the private worker, date, outcome, or underlying personnel document.

The governance question is nevertheless legitimate and independently testable:

What is the legal source, charter, membership, delegated authority, and decision scope of any CFMG body described as a physician board, physician committee, peer-review body, or comparable professional-governance group?

The answer should be sought in public or otherwise publishable versions of:

• bylaws;

• board resolutions;

• committee charters;

• delegation instruments;

• minutes or written consents filed in litigation;

• credentialing/peer-review governance documents;

• and sworn testimony describing the body's authority.

Until those materials are located, the correct public conclusion is that CFMG has identifiable physician corporate leadership while the relationship among its statutory board, any physician committee, and other professional-governance bodies remains incompletely documented.

A reported physician decision does not, by itself, complete the decision chain#

A governance question can be posed publicly without any private record: if a future public filing, deposition or produced document shows physician participation in a specific personnel decision, that would be direct evidence of professional governance in operation. Until then the question stays open.

The same sequence applies to any public decision event through the same sequence used elsewhere in the series: origin → recommendation → authorized professional review → approval or veto → implementation . A later physician ratification is not the same as an originating decision; a management recommendation is not the same as final authority; and mere alignment does not reveal who would prevail under disagreement.

The highest-value evidence is a conflict-tested record showing that an authorized CFMG physician body could say no and that the enterprise was required to follow its decision—or the reverse. Until such a public record is available, private personnel material should remain a research lead rather than a published merits proposition.

VI. Why the Issue Matters#

The stakes are practical rather than semantic. Counties need to know which entity is accountable for contracted performance; clinicians need to know where professional authority resides; courts and regulators need entity-specific evidence rather than brand shorthand; and the public needs a record that distinguishes corporate continuity from operational integration. Those distinctions become most important when the actors disagree, when a contract changes hands, when a professional decision conflicts with an economic preference, or when litigation requires a precise answer to who had authority to act.

Why county contracts are different from litigation positions#

A litigation filing is written to win a dispute.

A county contract is written to buy healthcare.

That distinction makes county records unusually valuable.

County procurement files can reveal:

• the bidder;

• the legal contracting party;

• the entity signing the agreement;

• the person signing;

• the entity receiving notices;

• the entity required to maintain insurance;

• the entity indemnifying the County;

• the proposed organizational chart;

• local and regional management;

• staffing requirements;

• medical-director responsibilities;

• clinical-quality requirements;

• EHR obligations;

• physician credentialing;

• pharmacy;

• utilization review;

• claims handling;

• payroll;

• employee relations;

• subcontractors;

• and whether Wellpath is identified as brand, manager, MSO, affiliate, successor, or contractor.

The client-side record is especially important because California counties were not passive observers. They negotiated and monitored the correctional-health programs.

If a county expressly understood that CFMG was the professional contractor and Wellpath the MSO, that is powerful evidence of the intended structure.

If another county called CFMG “now Wellpath,” “dba Wellpath,” or “dba Wellpath Management, Inc.,” that is powerful evidence of public operational identity , but not necessarily accurate corporate law.

The correct analysis is therefore:

What did the contract actually say, and what did the County staff report say?

Those can differ.

VII. Falsification Tests and Evidentiary Limits Note#

The record does not support be read as establishing an unproven motive, an undisclosed shareholder, an unlawful medical override, or a legal conclusion that a court or regulator has not made. The strongest version of the thesis is the one that survives the missing-document test: identify the instrument, minutes, ledger, delegation, approval record, or disagreement event that would materially change the conclusion, then state what has and has not been found. If later primary evidence contradicts a proposition stated here, the correction should be made at the proposition level rather than defended through branding or organizational shorthand.

VIII. Related Articles#

• Article 023 — Judd Bazzel: From Correct Care Clinical Executive to CFMG President

• Article 025 — Scott Kennedy and the Financial Side of Physician Governance

• Article 022 — Raymond Herr: The Physician Executive Who Bridges CFMG and the Enterprise

The proposition to be tested#

The central proposition in this article is not that every appearance of the Wellpath name proves control, nor that formal CFMG separateness ends the inquiry. The proposition to be tested is narrower: How should a Regional Medical Director and CFMG corporate officer be analyzed when the same person acts in both systems? A serious legal brief should state that proposition before discussing motive, liability, or remedy because the same document can be highly probative on one dimension and nearly irrelevant on another.

For this subject, the principal evidentiary dimensions are dual capacity, regional medical director, corporate office, and capacity attribution. The source spine identified in the current public record is: Wellpath proposal materials; CFMG contracts; corporate filings; Physician Board reference; capacity-ledger method. Those sources should not be pooled as though they were interchangeable. A county contract speaks most reliably to the county's counterparty and purchased obligations. A management agreement speaks to contractual allocation between the professional corporation and manager. A court order speaks to the matter actually adjudicated. A party filing or corporate announcement remains a representation unless independently adopted or found by a tribunal.

Governance evidence must distinguish office, employment, management title, board membership, shareholder status, delegated authority, and signature authority. These categories can overlap in one person without becoming legally interchangeable. The relevant capacity must be identified for each act. The practical advantage of that method is that it prevents a common failure in complex-enterprise investigations: using a true fact about one relationship as proof of a different relationship. A shared brand may show integration; a W-2 may show payroll identity; a contract signature may show authority to bind a corporation; an officer title may show corporate office. None automatically proves stock ownership or final clinical authority.

The charging or enforcement threshold, if any regulator ever considered one, would therefore require an evidence chain rather than a collage: identify the protected or regulated function; identify the actor with formal authority; reconstruct the first operative decision; identify the person or entity that could approve, reject, modify, or reverse it; and verify who implemented the result. Until that chain is complete, the proper classification is evidence, inference, or unresolved question—not adjudicated fact.

Weighing the evidence#

The evidentiary hierarchy for Richard Medrano: One Physician, Two Institutional Roles should begin with contemporaneous primary instruments and end with retrospective shorthand. Executed contracts, amendments, assignments, board resolutions, authenticated corporate records, court orders, government payroll or labor records, and formal agency records ordinarily deserve more weight on the proposition they were created to establish than marketing language or later summaries. Even among primary materials, however, purpose matters. A contract can establish contractual rights without proving that those rights were exercised; a tax record can establish reporting without deciding every common-law employer factor; a bankruptcy schedule can establish debtor treatment without answering professional-governance questions for a nondebtor corporation.

The article's existing record illustrates why that hierarchy matters.ithin its evidentiary lane. Core question. How should a Regional Medical Director and CFMG corporate officer be analyzed when the same person acts in both systems?

A prosecutor, defense lawyer, regulator, or investigative editor should ask five questions of every source: Who created it? What legal or business purpose did it serve? What date and entity does it concern? Is the statement a recital, operative term, allegation, stipulation, finding, or marketing representation? What independent record could confirm or contradict it? Applying those questions consistently is more valuable than multiplying citations that all derive from the same underlying assertion.

This also defines how contradictions should be handled. When two records use different labels, the first step is not to accuse one of being false. The first step is to determine whether the records were answering different questions. Only after normalizing entity, date, capacity, forum, and purpose should a remaining contradiction be treated as substantive. That discipline makes the article stronger for both sides because it identifies where the record genuinely conflicts and where the conflict is merely semantic.

Chronology as a control test#

Chronology is often more probative than organizational charts. The decisive question is not merely who possessed authority on paper, but when a decision became operative and what happened immediately before and after that moment. A later board vote, HR notice, county communication, or litigation position may confirm, ratify, or explain an earlier act without proving who made the initial decision. Conversely, an early recommendation may have no legal effect until the authorized professional or contracting entity adopts it.

For Richard Medrano: One Physician, Two Institutional Roles, the chronology should be reconstructed with document-level precision. Investigators should place each significant contract, amendment, email that has entered the public record, board action, personnel or agency event that is lawfully publishable, and court filing on a single timeline. Each entry should identify the actor, capacity, entity, action verb, and legal effect. Terms such as “recommended,” “approved,” “directed,” “implemented,” “ratified,” “reported,” and “terminated” are not synonyms. The wording can reveal whether a participant supplied information, exercised discretion, or merely carried out another actor's decision.

The current article supplies anchor points that should remain central. The governing question is narrow: How should a Regional Medical Director and CFMG corporate officer be analyzed when the same person acts in both systems? The article connects that question to juridical identity, operational integration, professional authority, ownership and succession, practical exit rights, and demonstrated veto power only where the evidence makes those connections material. How could a California physician-owned professional corporation be identified in federal corporate-disclosure filings as the “corporate parent” of Wellpath LLC, a national management entity, while public corporate materials describe CFMG as a Wellpath affiliate?

A robust chronology is also the best protection against overstatement. If the alleged controlling act occurred before the supposedly controlling actor entered the process, that theory weakens. If a professional body acted only after implementation, a claim that it supplied the first operative decision requires qualification. If the public record shows independent deliberation before implementation, that evidence materially strengthens the formal-independence account. The analysis therefore must treat time as an evidentiary variable, not just background narrative.

Sources and authorities#

1. Public records and authorities identified in the article body and source spine of the published record.